Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer
April 22, 2019 at 08:15 AM EDT
BERKELEY, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced the appointment of Dimitry S.A. Nuyten, M.D., Ph.D., as Chief Medical Officer.
“Dimitry’s expertise as a radiation oncologist specializing in cancer biology and his experience leading immuno-oncology clinical strategy and development will be instrumental to Aduro,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy.”
Dr. Nuyten will join Aduro from Pfizer where he most recently served as Vice President and Immuno-Oncology Clinical Development Leader and oversaw the clinical strategy for BAVENCIO® (avelumab), a human anti-programmed death ligand-1 (PD-L1) antibody, utomilumab, a human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB and additional programs that included pivotal and exploratory trials with immuno-oncology combinations. Prior to Pfizer, he served as Group Medical Director and Exploratory Development Team Leader at Bristol-Myers Squibb, where he was responsible for the development of several early phase compounds in oncology. Dr. Nuyten holds an M.D. from the University of Groningen and a Ph.D. from the University of Amsterdam Medical School in The Netherlands and completed his training in radiation oncology at the Netherlands Cancer Institute (NKI). He has authored numerous peer-reviewed publications and is co-inventor on multiple patents.
“I am excited to join Aduro and continue building the company’s leadership position in STING and APRIL biology,” said Dr. Nuyten. “I look forward to collaborating with Aduro’s clinical team and our external partners to generate additional data while making a meaningful impact for patients.”
Cautionary Note on Forward-Looking Statements
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f50d0fc9-729e-4821-a271-31dbf9303512